SUPPLEMENTARY DATA

Supplementary Table 1. Incidence of fractures per 100,000 person-years in the UK by age

|  |  |  |  |
| --- | --- | --- | --- |
| Age | Hip | Vertebral | NHNV |
| 50–54 | 33 | 84 | 633 |
| 55–59 | 51 | 142 | 813 |
| 60–64 | 81 | 143 | 979 |
| 65–69 | 132 | 192 | 1,425 |
| 70–74 | 282 | 397 | 1,928 |
| 75–79 | 619 | 602 | 2,891 |
| 80–84 | 1,236 | 777 | 3,876 |
| 85+ | 2,255 | 1,061 | 5,958 |

**Abbreviations:** NHNV: non-hip non-vertebral; UK: United Kingdom.  
**Source:** Singer et al. 1998 [1]

Supplementary Table 2. Distribution of clinical risk factors

|  |  |
| --- | --- |
| Risk factor | Mean or proportion (%) |
| Age | 70 |
| Body mass index | 29.4 |
| Femoral neck T-score | -3.0 |
| Previous fracture | 100% |
| Parent fractured hip | 22% |
| Current smoking | 18% |
| Glucocorticoids | 5% |
| Alcohol 3 or more units/day | 1% |
| Rheumatoid arthritis | 3% |

Supplementary Table 3. Population tariff values for UK

|  |  |
| --- | --- |
| Age | General population utility |
| 50 | 0.849 |
| 55 | 0.804 |
| 60 | 0.804 |
| 65 | 0.785 |
| 70 | 0.785 |
| 75 | 0.734 |
| 80 | 0.734 |

Abbreviations: UK: United Kingdom  
Source: Szende et al. 2014 [2]

Supplementary Table 4. Utility multipliers

|  |  |
| --- | --- |
| **Fracture type/period** | **Utility multiplier** |
| *First year after fracture* | |
| Hip fracture | 0.545 |
| Clinical vertebral fracture | 0.671 |
| Other (NHNV) fractures | 0.791 |
| *Second and following years after fracture* | |
| Hip fracture | 0.857 |
| Clinical vertebral fracture | 0.841 |
| Other (NHNV) fractures | 0.952 |

**Abbreviations:** NHNV: non-hip non-vertebral  
**Source:** International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) [3]

Supplementary Table 5. Cost of fractures

|  |  |
| --- | --- |
| **Fracture type/period** | **Cost (£, 2019)** |
| *First year after fracture* | |
| Hip fracture | 13,080 |
| Clinical vertebral fracture | 2,870 |
| Other (NHNV) fractures | 2,005 |
| *Second and following years after fracture* | |
| Hip fracture | 115 |
| Clinical vertebral fracture | 367 |

**Abbreviations:** NHNV: non-hip non-vertebral  
**Source:** Gutierrez, L., et al 2012 and 2011, Davis, S., 2015 [4, 5, 6]

References

1.  Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg (Br) 80(2):243–248

2. Szende A, Janssen B, Cabases J (2014) Self-reported population health: an international perspective based on EQ-5D. Springer, Dordrecht

3. Borgstrom F, Lekander I, Ivergard M, Strom O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson AN, Jonsson B, Kanis JA (2013) The international costs and utilities related to osteoporotic fractures study (ICUROS)--quality of life during the first 4 months after fracture. Osteoporos Int 24(3):811–823

4. Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S (2012) Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone 51(3):324–331

5. Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M (2011) Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ 14(1):99–107

6. Davis S (2015) Bisphosphonates for preventing osteoporotic fragility fractures (including a partial update of NICE technology appraisal guidance 160 and 161). Assessment report. Table 32., National Institute for Health and Care Excellence (NICE), Editor